WAC 246-650-020
Performance of screening tests. (1)
Hospitals providing birth and delivery services or neonatal
care to infants shall:
(a) Inform parents or responsible parties, by providing a
departmental information pamphlet or by other means, of:
(i) The purpose of screening newborns for congenital
disorders,
(ii) Disorders of concern as listed in WAC 246-650-020(2),
(iii) The requirement for newborn screening, and
(iv) The legal right of parents or responsible parties to
refuse testing because of religious tenets or practices as
specified in RCW 70.83.020, and
(v) The specimen storage, retention and access
requirements specified in WAC 246-650-050.
(b) Obtain a blood specimen for laboratory testing as
specified by the department from each newborn prior to
discharge from the hospital or, if not yet discharged, no
later than five days of age.
(c) Use department-approved newborn screening
specimen/information forms and directions for obtaining
specimens.
(d) Enter all identifying and related information
required on the specimen/information form following directions
of the department.
(e) In the event a parent or responsible party refuses to
allow newborn screening, obtain signatures from parents or
responsible parties on the department specimen/information
form.
(f) Forward the specimen/information form with dried
blood spots or signed refusal to the Washington state public
health laboratory no later than the day after collection or
refusal signature.
(2) Upon receipt of specimens, the department shall:
(a) Perform appropriate screening tests for:
(i) Biotinidase deficiency;
(ii) Congenital hypothyroidism;
(iii) Congenital adrenal hyperplasia;
(iv) Galactosemia;
(v) Homocystinuria;
(vi) Hemoglobinopathies;
(vii) Maple syrup urine disease (MSDU);
(viii) Medium chain acyl-coA dehydrogenase deficiency
(MCADD);
(ix) Phenylketonuria (PKU);
(x) Cystic fibrosis;
(xi) The amino acid disorders: Argininosuccinic acidemia
(ASA), citrullinemia (CIT), and tyrosinemia type I (TYR 1)
according to the schedule in WAC 246-650-030;
(xii) The fatty acid oxidation disorders: Carnitine
uptake defect (CUD), long-chain L-3-OH acyl-CoA dehydrogenase
deficiency (LCHADD), trifunctional protein deficiency (TFP),
and very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)
according to the schedule in WAC 246-650-030;
(xiii) The organic acid disorders: 3-OH 3-CH3 glutaric
aciduria (HMG), beta-ketothiolase deficiency (BKT), glutaric
acidemia type I (GA 1), isovaleric acidemia (IVA),
methylmalonic acidemia (CblA,B), methylmalonic acidemia
(mutase deficiency) (MUT), multiple carboxylase deficiency
(MCD), propionic acidemia (PROP) according to the schedule in
WAC 246-650-030;
(b) Report significant screening test results to the
infant's attending physician or family if an attending
physician cannot be identified; and
(c) Offer diagnostic and treatment resources of the
department to physicians attending infants with presumptive
positive screening tests within limits determined by the
department.
[Statutory Authority: Chapter 70.83 RCW. 08-13-073, §
246-650-020, filed 6/16/08, effective 7/17/08. Statutory
Authority: Chapters 70.83, 43.20 RCW. 06-04-009, §
246-650-020, filed 1/20/06, effective 2/20/06; 03-24-026, §
246-650-020, filed 11/24/03, effective 12/25/03. Statutory
Authority: RCW 43.20.050 and 70.83.050. 92-02-019 (Order
225B), § 246-650-020, filed 12/23/91, effective 1/23/92. Statutory Authority: RCW 43.20.050. 91-02-051 (Order 124B),
recodified as § 246-650-020, filed 12/27/90, effective
1/31/91. Statutory Authority: Chapters 43.20 and 70.83 RCW. 91-01-032 (Order 114B), § 248-103-020, filed 12/11/90,
effective 1/11/91. Statutory Authority: RCW 43.20.050 and 70.83.050. 87-11-040 (Order 303), § 248-103-020, filed
5/18/87.]